Oramed Pharmaceuticals (ORMP) Proxy filing summary

Executive summary

• Annual meeting scheduled for September 15, 2026, with voting available online or in person.

• Shareholders are encouraged to review proxy materials and vote on key proposals affecting governance and compensation.

Voting matters and shareholder proposals

• Election of six directors for a one-year term, with all nominees recommended by the board.

• Ratification of Kesselman & Kesselman as independent auditors for the fiscal year ending December 31, 2026.

• Approval sought for an amendment to increase shares under the Long-Term Incentive Plan by 3,000,000, totaling 12,500,000 shares.

• Advisory vote on executive compensation and on the frequency of future say-on-pay votes.

• Proposal to adjourn the meeting if additional time is needed for proxy solicitation.

Board of directors and corporate governance

• Six director nominees listed: Nadav Kidron, Dr. Miriam Kidron, Dr. Daniel Aghion, Dr. Arie Mayer, Yehuda Reznick, and Benjamin Shapiro.

• Directors to serve for one year or until successors are elected and qualified.